Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-974]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: Cedarburg Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2022. Such persons may also file a written request for a hearing on the application on or before April 26, 2022.
 ADDRESSES: DEA requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to 
                        *http://www.regulations.gov*
                         and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on 
                        *http://www.regulations.gov.*
                         If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.”


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on August 27, 2021, Cedarburg Pharmaceuticals, 870 Badger Circle, Grafton, Wisconsin 53024-0000, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance
Drug code
ScheduleLysergic Acid Diethylamide
7315
ITetrahydrocannabinols
7370
I4-Bromo-2,5-Dimethoxyphenethylamine
7392
I3,4-Methylenediocyamphetamine
7400
I3.4-Methylenedioxymethamphetamine
7405
I5-Methoxy-N-N-dimethltryptamine
7431
IDimethyltryptamine
7435
IPsilocybin
7437
IPsilocyn
7438
IMethylphenidate
1724
IINabilone
7379
II4-Anilino-N-Phenethyl-4-Piperidine (ANPP)
8333
IIFentanyl
9801
II
 The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. In reference to the drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture as synthetic. No other activity for this drug code is authorized for this registration. Matthew J. Strait, Deputy Assistant Administrator.


[FR Doc. 2022-04064 Filed 2-24-22; 8:45 am] BILLING CODE 4410-09-P